Navigation Links
InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application
Date:5/4/2010

=s_gi(s_account);s.linkTrackVars='prop5,eVar3,prop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='92799664';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.intermune.com">www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 1-800-642-1687 (U.S.) or 1-706-645-9291 (international), and entering the conference ID# 73229257.  

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, which reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated regulatory timelines and the likelihood of regulatory success. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements. Pirfenidone failed to achieve statistical significance on the primary endpoint in one of its two pivotal clinical trials and there can be no assurance that the regulatory authorities in either the United States or Europe will grant regulatory approval based upon these data, in combination with the other efficacy analyses and safety results the company has submitted in support of its NDA and MAA filings. Other factors that could cause or contribute to such differences include, but are not limited
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. InterMune to Release First Quarter Financial Results on April 29
2. InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
3. InterMune Announces Proposed Public Offering of Common Stock
4. InterMune to Release Third Quarter Financial Results on November 5
5. InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
6. InterMune to Present at Canaccord Adams Conference
7. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
8. InterMune to Release Second Quarter Financial Results on August 6
9. InterMune to Present at Goldman Sachs Healthcare Conference
10. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
11. InterMune to Release First Quarter Financial Results on April 30
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015  US-Australian drug discovery company, Novogen Limited ... its comprehensive scientific review has identified high value ... of unmet patient need. Novogen is moving as ... prior to entering into Phase 1 clinical trials ... Chief Executive Officer, Iain Ross , said ...
(Date:8/31/2015)... FRANCISCO, Calif. , Aug. 31, 2015 ... discovery and development of novel cancer immunotherapies, announced today ... Ph.D., as Chief Executive Officer and William Ho ... and Ho join an experienced management team led by ... Jordan Fridman , Ph.D., Chief Scientific Officer; Jay ...
(Date:8/31/2015)... -- Trimb Healthcare AB ("Trimb") today announced that it ... ("YouMedical"), a Dutch OTC company with operations in key ... EUR 16 million, with solid growth and leading brands ... to build a leading international OTC company, and this ... gives us a stronger North European OTC platform, from ...
(Date:8/31/2015)... ... 2015 , ... The Food Processing Suppliers Association's PROCESS EXPO ... manufacturers and leaders in the field of academia. , METTLER TOLEDO will ... of bakery and snacks; beverages; dairy; meat, poultry and seafood; and prepared foods. ...
Breaking Biology Technology:Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4METTLER TOLEDO Hosts Food Safety Educational Center at 2015 PROCESS EXPO 2
... Rhythm announced today the results of a Phase 1b ... for the treatment of diabetic gastroparesis. The trial demonstrated ... diabetic gastroparesis. The findings were presented at the Digestive ... The Phase 1b clinical trial was a randomized, double-blind, ...
... To become better healers, tissue engineering need a timely and ... already are or can become the tissue they need to ... that the stiffness, viscosity, and other mechanical properties of adult ... predict whether they will turn into bone, cartilage, or fat. ...
... New York, May 21, 2012 Elsevier,s Computers & ... on 3D Object Retrieval which will incorporate the Collage Authoring ... place winner of the 2011 Executable Paper Grand Challenge. The ... Eurographics 2012 on May 13, during the 3DOR Workshop. ...
Cached Biology Technology:Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Diabetic Gastroparesis 2Physical properties predict stem cell outcome 2Physical properties predict stem cell outcome 3
(Date:8/5/2015)... According to a new market research report, ... (BFSI, Airport, IT & Telecom, Utilities, Education, Defense & ... published by MarketsandMarkets, defines and segments the Physical Identity ... global PIAM Market is estimated to grow from $272.2 ... a CAGR of 14.9 % from 2014 to 2019. ...
(Date:8/4/2015)...  AMRI (NASDAQ: AMRI ) today reported financial and operating ... Highlights: , Second quarter contract revenue of $ ... , Adjusted contract margins of 26 % ... $0.05 decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial quarter, ...
(Date:7/31/2015)... 31 de julho de 2015 A 10 ... ) será realizada pela BGI de 22-25 de outubro de ... A conferência está celebrando seu 10 o. ... ICG se tornou uma das reuniões mais influentes do ... científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... Research expresses its congratulations to and appreciation of ... 2010 Leadership in Personalized Medicine Award from the Personalized ... distinguished member of the AACR for more than 20 ... the Harvard Personalized Medicine Conference on Nov. 17. According ...
... burn fossil fuels remain the main source of electricity ... to remove sulfur compounds from their flue gases, which ... researchers in India have devised a way to convert ... value-added products. They describe details in the International ...
... of a fruit fly embryo, which was taken by ... beaten-off stiff competition from hundreds of entries to win ... biodiversity. Samantha Warrington, a postgraduate student from the ... in the ,close-up category, at the Society of Biology,s ...
Cached Biology News:AACR congratulates William S. Dalton on 2010 Leadership in Personalized Medicine Award 2Snap of fruit fly embryo wins scientific photo competition 2
... detector is an optical unit that can ... or Dyad Disciple gradient-capable thermal cycler (purchased ... photonics shuttle that contains four LEDs for ... nm, 620-650 nm) and two filtered photodiodes ...
... sensitive laser confocal systems designed for rapid ... that meet your expectations, differentiating between a ... the signal on the bottom as well ... for increased sensitivity. Results with VersArray ChipReader ...
... perform 96 assays on four slides. The ... slides with 96 (6mm x 7mm) individual ... expression, or screening analysis studies. Unlike other ... gasket, eliminating the presence of contaminating adhesives. ...
... with sequence siTrio siRNA --- a ... target gene of interestis our most popular product. ... 75% knockdown of your target gene when used ... and confirmation of optimal transfection with one of ...
Biology Products: